Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

scientific article published on June 28, 1997

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID9217756

P433issue9069
P407language of work or nameEnglishQ1860
P921main subjectplaceboQ269829
placebo-controlled trialQ108853737
P1104number of pages7
P304page(s)1857-1863
P577publication date1997-06-01
1997-06-28
P1433published inThe LancetQ939416
P1476titleRandomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
P478volume349

Reverse relations

cites work (P2860)
Q304990451999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension
Q365723552013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations
Q924630602018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations
Q376561897th Brazilian Guideline of Arterial Hypertension: Chapter 8 - Hypertension and Associated Clinical Conditions
Q42932007A new mechanism for albuminuria-induced podocyte injury
Q37682240A predictive model of progression of CKD to ESRD in a predialysis pediatric interdisciplinary program
Q35276839A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy
Q36666911ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy
Q35012428ACE inhibition is renoprotective among obese patients with proteinuria
Q79209601ACE-inhibitors-induced metabolic acidosis in a child with nephrotic syndrome
Q34244029Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature
Q48320229Achieving remission of proteinuria in childhood CKD.
Q36323673Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis
Q24657470Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy
Q33291468Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis
Q35819435Albuminuria as a marker of arterial stiffness in chronic kidney disease patients.
Q58701697Albuminuria during treatment with angiotensin type II receptor blocker is a predictor for GFR decline among non-diabetic hypertensive CKD patients
Q33414957Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
Q28344356Aldosterone as a determinant of cardiovascular and renal dysfunction
Q46286077Aliskiren combined with losartan: Thor's hammer or Sigurd's sword?
Q35876368Aliskiren in hypertension: evidence for its potential therapeutic value
Q84234871Alport syndrome: About time--treating children with Alport syndrome
Q33737225Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.
Q35087034Angiotensin II and the glomerulus: focus on diabetic kidney disease
Q37526033Angiotensin II increases glomerular permeability by β-arrestin mediated nephrin endocytosis
Q35855619Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall
Q85723580Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin
Q36063285Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies
Q35027660Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer
Q35918820Antihypertensive drugs and the kidney
Q42688526Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis
Q33561456Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects
Q74299116Antihypertensive therapy and progression of chronic renal disease
Q26865691Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system
Q43871012Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation
Q36255428Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention
Q36026304Antioxidants in kidney diseases: the impact of bardoxolone methyl
Q34738508Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?
Q34531105Arthropathy and proteinuria: nail-patella syndrome revisited
Q35658644Assessment and management of hypertension in transplant patients
Q91676304Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. Statistical Regression Modeling to P
Q37152477Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study
Q84230097Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease
Q28386914Blood lead level and measured glomerular filtration rate in children with chronic kidney disease
Q37593685Blood pressure level and kidney disease progression: do we really need to go to 130/80 mm Hg?
Q34990479Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease
Q36392732CKiD (CKD in children) prospective cohort study: a review of current findings.
Q41682196Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance
Q37950891Cardiorenal connection in chronic kidney disease.
Q36245164Cardiorenal disease: a clinical intersection
Q84563746Cardiovascular disease in patients with chronic kidney disease
Q37437174Cardiovascular implications of proteinuria: an indicator of chronic kidney disease
Q38155422Changes in renal function in congestive heart failure
Q37261346Characteristics of uninsured Americans with chronic kidney disease
Q90264301Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets
Q36120049Chronic kidney disease in children: the global perspective
Q34367656Chronic kidney disease prediction is an inexact science: The concept of "progressors" and "nonprogressors"
Q38087529Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options
Q89873152Clinical burden of autosomal dominant polycystic kidney disease
Q34736194Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America
Q30499043Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.
Q47389835Clinical study on Yishen Qufeng Shengshi Recipe () for glomerular proteinuria patients: A randomized controlled trial
Q35838496Compelling drug indications in diabetic and nondiabetic nephropathy
Q33376840Complement in glomerular injury
Q34455207Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome
Q43682745Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance
Q35895018Cost-effectiveness of chronic kidney disease mass screening test in Japan
Q36426101Cost-effectiveness of screening for microalbuminuria among African Americans
Q37495555Current and emerging treatment options for the elderly patient with chronic kidney disease
Q37087865Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Q49719393Dietary Approach to Stop Hypertension (DASH) diet and risk of renal function decline and all-cause mortality in renal transplant recipients.
Q35210221Dipstick proteinuria as a screening strategy to identify rapid renal decline
Q49728191Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease
Q37417576Direct renin inhibitors: ONTARGET for success?
Q37070295Do we learn the right things from clinical trials?
Q37779518Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?
Q36794965Does remission of renal disease associated with antihypertensive treatment exist?
Q24816744Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?--A systematic review
Q37012488Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study.
Q53076372Doubling of serum creatinine: is it appropriate as the endpoint for CKD? Proposal of a new surrogate endpoint based on the reciprocal of serum creatinine
Q35903126Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Q34005812Drug-induced respiratory disorders: incidence, prevention and management
Q37593689Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?
Q37053287Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?
Q35025425Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset
Q37318279Early pancreas graft failure is associated with inferior late clinical outcomes after simultaneous kidney-pancreas transplantation
Q38042582Educational paper: Progression in chronic kidney disease and prevention strategies
Q38372995Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial
Q92862014Effect of Renin-Angiotensin System Blockade on Mortality in Korean Hypertensive Patients with Proteinuria
Q34391982Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease
Q36434830Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial
Q33733552Effect of benazepril on the transdifferentiation of renal tubular epithelial cells from diabetic rats.
Q37593687Effect of blood pressure lowering on markers of kidney disease progression
Q58728699Effect of common storage temperatures and container types on urine protein : creatinine ratios in urine samples of proteinuric dogs
Q36127484Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
Q37060053Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).
Q37671099Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan
Q33900224Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial
Q36258891Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial
Q51321869Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.
Q36662162Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
Q34629667Effects of intensive low-salt diet education on albuminuria among nondiabetic patients with hypertension treated with olmesartan: a single-blinded randomized, controlled trial
Q47136700Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study
Q92535844Efficacy and Safety of Sodium Tanshinone IIA Sulfonate Injection on Hypertensive Nephropathy: A Systematic Review and Meta-Analysis
Q34141784Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial
Q46339940Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study
Q37962590Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
Q35905899Emerging drug combinations to optimize renovascular protection and blood pressure goals
Q37489497Emerging therapies for chronic kidney disease: what is their role?
Q46371599Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial
Q44743920Enalapril in children with Alport syndrome
Q37809748Epidemiology of hypertensive kidney disease
Q34045991Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease
Q35658629Evaluating risk of ESRD in the urban poor
Q30381245Extracorporeal shock wave therapy does not improve hypertensive nephropathy.
Q34945403Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Q56336831First-line drugs for hypertension
Q36700001Genetic polymorphisms of the RAS-cytokine pathway and chronic kidney disease
Q24657844Guidelines for the management of chronic kidney disease
Q27687254Health-related quality of life in hypertension, chronic kidney disease, and coexistent chronic health conditions
Q34966853Hepatitis C and kidney disease: An overview and approach to management
Q36500612High burden and unmet patient needs in chronic kidney disease
Q51027996High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients
Q34841427Homelessness and risk of end-stage renal disease
Q35203404Hypertension in Cardiovascular and Kidney Disease
Q92409094Hypertension in Childhood Nephrotic Syndrome
Q36407313Hypertension in children with chronic kidney disease: pathophysiology and management
Q35071147Hypertension in chronic kidney disease: navigating the evidence
Q35940034Hypertension management: special considerations in chronic kidney disease patients
Q35686224Hypertensive renal damage: insights from animal models and clinical relevance
Q36666997Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention
Q36834059Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines
Q38068099Improving the efficacy of RAAS blockade in patients with chronic kidney disease
Q35660098Incomplete Restoration of Angiotensin II-Induced Renal Extracellular Matrix Deposition and Inflammation Despite Complete Functional Recovery in Rats
Q36129853Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease
Q34616311Inflammation and cachexia in chronic kidney disease
Q90068105Inhibition of Endocytosis of Clathrin-Mediated Angiotensin II Receptor Type 1 in Podocytes Augments Glomerular Injury
Q37243981Inhibition of the renin-angiotensin system and chronic kidney disease
Q57702269Intensified inhibition of renin-angiotensin system: A way to improve renal protection?
Q37051491Intensified inhibition of renin-angiotensin system: a way to improve renal protection?
Q98178857Interventions to Improve Blood Pressure Control Among Socioeconomically Disadvantaged Patients With CKD: Kidney Awareness Registry and Education Pilot Randomized Controlled Trial
Q35765142Is proteinuria a plausible target of therapy?
Q92578316KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
Q37913979Kidney aging--inevitable or preventable?
Q37184178Kidney disease in nail-patella syndrome
Q33738621Kidney dysfunction in patients with pulmonary arterial hypertension
Q35853283Kidney function can improve in patients with hypertensive CKD
Q36590834Lessons from the African-American Study of Kidney Disease and Hypertension: an update
Q37547378Life expectancy with chronic kidney disease: an educational review
Q48035532Long-term outcome of childhood IgA nephropathy with minimal proteinuria
Q85601530Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome
Q33503903Low documentation of chronic kidney disease among high-risk patients in a managed care population: a retrospective cohort study
Q57750140Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA
Q38249892Management of hyperkalaemia in chronic kidney disease
Q99403175Management of proteinuria: blockade of the renin-angiotensin-aldosterone system
Q36443751Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials
Q37892340Managing kidney disease with blood-pressure control
Q37364008Matrix Producing Cells in Chronic Kidney Disease: Origin, Regulation, and Activation.
Q34185922Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study
Q34331403Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
Q37291040Membranous glomerulonephritis: treatment response and outcome in children
Q36922222Membranous nephropathy in the older adult: epidemiology, diagnosis and management
Q35861444Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals
Q33668247Misdiagnosis and mistreatment of a common side-effect--angiotensin-converting enzyme inhibitor-induced cough
Q35128415Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial
Q38062404Molecular targets for treatment of kidney fibrosis
Q34011001Nephrology: 2. Evaluation of asymptomatic hematuria and proteinuria in adult primary care
Q50451777Nephrotic range proteinuria as a strong risk factor for rapid renal function decline during pre-dialysis phase in type 2 diabetic patients with severely impaired renal function
Q24650808Nephrotic syndrome in adults
Q37381991New Generation Calcium Channel Blockers in Hypertensive Treatment
Q37219043Novel drugs and intervention strategies for the treatment of chronic kidney disease
Q37014196Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review
Q37114337Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study
Q37283558Obstructive renal injury: from fluid mechanics to molecular cell biology
Q64073930Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
Q37593679Outcomes of antiproteinuric RAAS blockade: high-dose compared with dual therapy
Q42048902Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis
Q37219039Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease
Q35758311Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition
Q90066192Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study
Q43121487Posterior urethral valves: Persistent renin angiotensin system activation after valve ablation and role of pre-emptive therapy with angiotensin converting enzyme-inhibitors on renal recovery
Q37307975Potential risks of calcium channel blockers in chronic kidney disease
Q90182803Preventing CKD in Low- and Middle-Income Countries: A Call for Urgent Action
Q38221804Preventing the progression of chronic kidney disease: two case reports and review of the literature.
Q34979484Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis
Q37414937Proteinuria and its relation to cardiovascular disease
Q36919041Proteinuria as a Therapeutic Target in Advanced Chronic Kidney Disease: a Retrospective Multicenter Cohort Study
Q30886088Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Data from the Ital Kid Project
Q37115067Proteinuria in systemic sclerosis: reversal by ACE inhibition
Q37990717Proteinuria should be used as a surrogate in CKD.
Q33710875Proteinuria, (99m) Tc-DTPA Scintigraphy, Creatinine-, Cystatin- and Combined-Based Equations in the Assessment of Chronic Kidney Disease.
Q35753157Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis.
Q34698778Ramipril: a review of its use in the prevention of cardiovascular outcomes
Q84388652Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients
Q33683988Randomized, double-blind, controlled study of losartan in children with proteinuria.
Q50674690Rate of Decline of Residual Kidney Function Before and After the Start of Peritoneal Dialysis
Q38110184Rational use of antihypertensive medications in children
Q33811023Recent advances: nephrology
Q36840918Recognition and management of chronic kidney disease in an elderly ambulatory population
Q34433011Reduced incidence of end stage renal disease among the elderly in Denmark: an observational study
Q35028657Remission of renal disease: recounting the challenge, acquiring the goal
Q35069799Renal function can improve at any stage of chronic kidney disease
Q24791709Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys
Q33649627Renal protection and antihypertensive drugs: current status
Q36362572Renal protection in hypertensive patients: selection of antihypertensive therapy
Q37051466Renal protection: are all antihypertensive drugs comparable?
Q28363418Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1
Q79157988Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
Q37051483Renin inhibitors: optimal strategy for renal protection
Q80387822Renin-angiotensin axis blockade reduces proteinuria in presymptomatic patients with familial FSGS
Q36677632Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis
Q34277800Renoprotective therapy in patients with nondiabetic nephropathies
Q36082302Retarding the progression of chronic kidney disease with renin angiotensin system blockade
Q47669329Revisiting RAAS blockade in CKD with newer potassium-binding drugs
Q33983415Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP)
Q34169794Risk factors for progression of chronic kidney disease
Q75193593Risk factors for renal failure in children with non-glomerular nephropathies
Q36089280Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis
Q37591514Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged >or=65 years
Q36677647Role of remission clinics in the longitudinal treatment of CKD.
Q30429844Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease
Q34306932Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?
Q38417868Roles of lymphocyte kv1.3-channels in the pathogenesis of renal diseases and novel therapeutic implications of targeting the channels.
Q24650910Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
Q64111991Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial
Q52648659Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.
Q37593682Should albuminuria be a focus of antihypertensive therapy goals?
Q26864582Sickle cell disease in children
Q45330840Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy
Q35803318Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients
Q37103758Slowing chronic kidney disease progression: results of prospective clinical trials in adults
Q35153298Slowing nephropathy progression: focus on proteinuria reduction
Q35904809Slowing the progression of adult chronic kidney disease: therapeutic advances.
Q35720736Sodium intake, ACE inhibition, and progression to ESRD.
Q35887931Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
Q33805069Stem cell-based cell therapy for glomerulonephritis
Q28078020Stop chronic kidney disease progression: Time is approaching
Q46724848Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD).
Q38545793Syndrome of rapid onset end stage renal disease in incident Mayo Clinic chronic hemodialysis patient
Q54706881Target blood pressure for antihypertensive therapy in patients with proteinuric renal disease.
Q36359042The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.
Q33571347The HALT polycystic kidney disease trials: design and implementation
Q36259972The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.
Q35818244The Kidney Awareness Registry and Education (KARE) study: protocol of a randomized controlled trial to enhance provider and patient engagement with chronic kidney disease
Q33325660The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.
Q37741783The RAAS in the pathogenesis and treatment of diabetic nephropathy
Q43906046The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials
Q34455113The association between a Mediterranean-style diet and kidney function in the Northern Manhattan Study cohort
Q36557863The association of chronic kidney disease with the use of renin-angiotensin system inhibitors after acute myocardial infarction
Q38224257The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis
Q36306581The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease
Q37623107The current state of RAAS blockade in the treatment of hypertension and proteinuria
Q99625205The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
Q37738159The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease.
Q57701326The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease
Q47927287The membrane attack complex, C5b-9, up regulates collagen gene expression in renal tubular epithelial cells.
Q36875566The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol
Q45906510The peritoneal-renal syndrome.
Q36467553The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy
Q36421051The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension
Q81877802The role of calcium antagonists in patients with chronic renal failure
Q41206891The role of renin angiotensin system inhibition in kidney repair.
Q38256462The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis
Q35614311Therapeutic approach to FSGS in children
Q36510669Therapeutic strategies to slow chronic kidney disease progression
Q35720839Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy
Q46339985Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa.
Q38689787Treatment of IgA nephropathy with renal insufficiency
Q87035617Treatment of idiopathic membranous nephropathy
Q78814998Treatment of lupus nephritis
Q34549650Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?
Q36380142Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging
Q36951760Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases
Q47345092Urinary creatinine excretion and protein/creatinine ratios vary by body size and gender in children
Q34325372Urinary sodium excretion has positive correlation with activation of urinary renin angiotensin system and reactive oxygen species in hypertensive chronic kidney disease.
Q35209091Use of calcium antagonists in renal patients: therapeutic benefit or medical malpractice?
Q43214286Usefulness of RAS inhibition depends on baseline albuminuria.
Q89087608Vascular type 1 angiotensin receptors control blood pressure by augmenting peripheral vascular resistance in female mice
Q46639802What do we know about chronic renal failure in young adults? II. Adult outcome of pediatric renal disease
Q34365090What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?
Q37721287When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes
Q35673984World Kidney Day 2011 - Protect your kidneys, save your heart
Q83242372World Kidney Day 2011: protect your kidneys, save your heart
Q33871733World kidney day 2011: protect your kidneys, save your heart
Q34803864[Hypertension and the kidney].
Q83552993[Kidney and hypertension]
Q82520575[Sequelae of hypertenson: kidney disease]

Search more.